Back to rankings

BioMarin Pharmaceutical Inc. (BMRN)

Overvalued
HealthcareBiotechnologyUnited States

Fundamental

59

Price

$60.00

Market Cap

$11.88B

Part 1 · What the company is worth

Overview

BioMarin develops and sells therapies for rare, mostly genetic diseases — conditions so uncommon that few other companies develop treatments for them. Its drugs typically require a lifetime of dosing and enter their markets close to unopposed, since patient populations are too small for most competitors to justify the cost of a rival drug. It sells to a small, specialised base of treatment centres and physicians worldwide, not to the mass consumer market.

How it makes money

Revenue comes from chronic-use drugs administered for a patient's lifetime, mostly billed to insurers and national health systems with whom BioMarin negotiates pricing and reimbursement market by market. Voxzogo, its newest and fastest-growing therapy for a rare bone-growth disorder, has become the single largest product; a group of five older drugs the company calls Enzyme Therapies still supplies the majority of revenue from established treatments with long track records.

Revenue by segment

Enzyme Therapies65.4%

Group of five older enzyme-replacement drugs (Vimizim, Naglazyme, Palynziq, Aldurazyme, Brineura) treating separate rare metabolic disorders.

Voxzogo28.8%

Therapy for achondroplasia, a rare cause of disproportionate short stature; BioMarin's newest and fastest-growing product.

Kuvan3.1%

Older therapy for phenylketonuria, a rare metabolic disorder, now facing generic competition.

Other revenues1.6%

Royalty and licensing revenue earned outside the company's main marketed-product portfolio.

Roctavian1.1%

Gene therapy for severe haemophilia A, launched more recently and still building patient uptake.

Competitive moat

Patents and licences · Narrow

Patents, orphan-drug exclusivity and the sheer difficulty of developing a rival treatment for a disease affecting only a few thousand patients worldwide give BioMarin years of largely uncontested pricing once a drug is approved. The advantage erodes over time, though: Kuvan lost most of its revenue to generic competition once its exclusivity expired, showing the protection is temporary rather than permanent.

What drives demand

Defensive

Demand is driven by diagnosed patients needing lifelong treatment for a genetic condition, not by economic conditions or seasonal buying patterns, which makes volumes relatively stable through a downturn. The bigger swing factor is reimbursement: a health system or insurer narrowing what it will pay for a given therapy can reduce revenue even when patient need is unchanged.

Key risks

  • Patent and exclusivity expiration — Loss of patent protection or orphan-drug exclusivity opens the door to generic or biosimilar competition, as already happened with Kuvan, directly reducing revenue on the affected product.
  • Pricing and reimbursement pressure — High per-patient treatment costs depend on continued coverage from insurers and national health systems; tightening reimbursement or government price controls can reduce revenue even without new competition.
  • Rare-disease competition — A crowded field of new entrants developing rival gene and enzyme therapies for the same small patient populations could erode BioMarin's largely uncontested position in specific diseases.
  • Concentration in a narrow product set — A large share of revenue rests on a handful of therapies, Voxzogo and the Enzyme Therapies group; a safety issue, manufacturing problem or loss of exclusivity on any one of them has an outsized effect on total revenue.

Customer concentration

BioMarin sells largely to specialty distributors, health systems and government payers across many countries rather than to a small number of large commercial customers, and does not disclose a concentrated buyer as a material risk.

The case for

Buyers point to Voxzogo's rapid growth, the durability of an established enzyme-therapy portfolio treating diseases with little competition, and orphan-drug economics that let BioMarin price for the cost of development across a very small patient base.

The case against

Sellers fear that reimbursement pressure from insurers and governments, patent expirations that have already hit Kuvan, and a growing wave of rival gene and enzyme therapies could compress margins on a revenue base still concentrated in a handful of drugs.

Written by the editors, published on August 18, 2026

Direct competitors

Who this company fights with for the same customers

Compare

Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users

P/E: 17.8Score: 64Market cap: $14.99B

Ascendis sells a long-acting CNP therapy for achondroplasia that targets the very same children treated with Voxzogo, BioMarin's single largest product, and is the rival BioMarin's own 10-K names first in that indication.

P/E: 8.3Score: 66Market cap: $5.41B

PTC's Sephience (sepiapterin), approved for phenylketonuria, competes for the same PKU patients that BioMarin treats with Kuvan and Palynziq, including those who never responded to Kuvan.

P/E: —Score: 44Market cap: $1.48B

Ultragenyx builds its portfolio in the same ultra-rare metabolic and genetic diseases, with an approved enzyme therapy for MPS VII sitting directly alongside BioMarin's mucopolysaccharidosis products.

Sanofi S.A.Not tracked

Through its Genzyme rare-disease unit Sanofi markets enzyme replacement therapies for lysosomal storage disorders, sold to the same metabolic-disease centres and payers that buy Naglazyme, Vimizim and Aldurazyme.

Takeda Pharmaceutical Company Limited (武田薬品工業株式会社)Not tracked

Takeda's rare genetic disease franchise, including enzyme replacement therapies for Hunter syndrome and Gaucher disease, competes for the same small population of rare metabolic patients and the same specialist prescribers.

Balance Sheet & Liquidity

Revenue

$3.41B

Trailing 12 months (through 6/30/2026)

Net Income

$73M

Trailing 12 months (through 6/30/2026)

Free Cash Flow

$725M

Total Equity

$6.09B

Total Liabilities

$1.51B

Current Ratio

2.39

Interest Coverage

1.95

Debt/EBITDA

8.56

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseOvervalued

Fair Value

$49.79

Current Price

$60.00

Margin of Safety

-20.5%

Fair Value Range

$32.37 - $67.22

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$91.62
Discounted cash flow (DCF):$67.79
Earnings multiple (P/E):$5.79
Graham growth formula:$2.77
Earnings power value (EPV):$7.58
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:$35.41
Mid-cycle earnings:Not enough data to compute it
Revenue multiple:$69.02
Analyst Consensus:Strong Buy (27B / 8H / 0S)
Last Earnings Surprise:+4.05%

Valuation Metrics

P/E Ratio

153.85

ROE

5.7%

P/B Ratio

1.84

P/FCF

15.73

Gross Margin

76.1%

ROIC

1.2%

Profitability Radar

Value Creation (Economic Moat)

ROIC

1.2%

WACC

6.0%

ROIC − WACC

-4.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental Analysis Criteria

Passed (15)

  • EPS shows upward trend
  • EPS CAGR 11.34%
  • Gross Margin 76.1%
  • P/FCF 15.73
  • P/B Ratio 1.84
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Revenue Growth 5Y 11.6%
  • Analyst Consensus 77% Buy
  • Earnings Quality (OCF/NI) 11.75
  • Share Dilution 0.4%
  • Piotroski F-Score 5/9

Failed (11)

  • Price CAGR -2.82%
  • ROIC 1.2%
  • Operating Margin 4.4%
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 1.2%
  • Earnings Surprise avg -76.3%
  • Net Margin Trend 2.1% vs 21.5%

Unavailable (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

5/9

Mixed signals: some areas need attention

score
criteria

Earnings Quality

11.75

High quality: earnings backed by cash

Share Dilution

0.4%

Share count is stable

Institutional Holdings

Governance

Executive Team

NameTitleAge
Mr. Alexander HardyPresident, CEO & Director56
Mr. Brian R. Mueller CPACFO & Executive VP of Finance51
Dr. C. Greg Guyer Ph.D.Executive VP & CTO63
Ms. Cristin HubbardExecutive VP & Chief Commercial Officer-
Dr. Gregory Friberg M.D.Executive VP and Chief Research & Development Officer-
Ms. Rashmi Eshwar RamchandaniVP, Chief Accounting Officer & Principal Accounting Officer46
Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early Development-
Mr. Arpit DaveExecutive Vice President, Chief Digital & Information Officer-
Mr. George Eric Davis J.D.Executive VP, Chief Legal Officer & Secretary54
Ms. Amy WiremanExecutive VP & Chief People Officer-

Audit Risk

4

Board Risk

3

Compensation Risk

4

Shareholder Rights Risk

3

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-26

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-08-06

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-09-30

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Latest News

Recent headlines for BMRN, sourced from Markets Gazette.

  • 3/2/2026POSITIVE
    BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

    BioMarin Pharmaceutical Inc. has secured a significant regulatory win with the U.S. Food and Drug Administration (FDA) approving its supplemental Biologics License Application (sBLA) for Palynziq. This approval expands the use of the phenylketonuria (PKU) treatment to adolescents aged 12 and older. The expanded patient target group represents a substantial strengthening of BioMarin's PKU portfolio, unlocking new market opportunities and boosting the drug's revenue potential. For investors, this news is a clear positive signal, indicating growth in the treatable patient base and deeper market penetration for a key product, solidifying its leadership position in the rare disease sector.

  • 2/23/2026NEUTRAL
    Earnings Summary: BioMarin Pharmaceutical Q4

    BioMarin Pharmaceutical has reported its financial results for the fourth quarter, a key event for investors monitoring the biopharmaceutical company's performance. Market attention is now focused on the detailed analysis of the financial statements, including total revenues, earnings per share (EPS), and the sales performance of its main drugs. Of particular importance will be the guidance provided by management for the upcoming quarters, which will offer insights into the future growth trajectory and business outlook. In the absence of specific figures on whether the results beat or missed analyst estimates, the release of the earnings report is an informational yet neutral event, pending a clear market reaction.

via Markets Gazette